-
EHA Reflections | Professor Yizhen Li’s Plenary Session Presentation: CD5 Inhibition as a Universal Strategy to Broadly Enhance T-Cell Engager Antitumor Activity
At the highly anticipated Plenary Session of the 2026 European Hematology Association (EHA) Congress, Professor Yizhen Li from the Children’s Hospital of Soochow University presented his team’s original research findings.
-
EHA Reflections | Professor Heng Mei’s Team Reports Landmark LBA Study: BCMA CAR-T–Mediated Immune Reset Opens a New Era of Functional Cure for Refractory ITP
Refractory immune thrombocytopenia (ITP) remains a major clinical challenge. Characterized by frequent relapses, chronic treatment dependence, and limited curative options, many patients struggle to achieve durable remission despite multiple lines of therapy.
-
Director Zhihui Li: Two Original Studies Redefine Post-Transplant Prognosis and Highlight Five Key Advances in Hematopoietic Transplantation
At the 2026 European Hematology Association (EHA) Congress, the team led by Director Zhihui Li from Beijing GoBroad Boren Hospital presented two studies selected for poster presentation.
-
Breaking Biomarker Barriers: ASCENT-03 Study Confirms Universal Advantage of Sacituzumab Govitecan in 1L TNBC
Triple-negative breast cancer (TNBC) has always been a challenge in clinical treatment due to its high heterogeneity, high risk of recurrence, and poor prognosis. For patients with first-line (1L) advanced TNBC who are not eligible for immune checkpoint inhibitors (PD-1/L1 inhibitors), the benefits of traditional single-agent chemotherapy are limited. The emergence of antibody-drug conjugates (ADCs)…
-
EHA Reflections | Professor Lei Fan’s Late-Breaking Oral Presentation: World’s First In Vivo Dual-Target CAR-T LB2501 Reshapes the Treatment Landscape for Lymphoma
At the 2026 European Hematology Association (EHA) Congress, the field of cellular therapy witnessed a landmark breakthrough. During a prestigious Late-Breaking Oral Session, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented the first-ever clinical proof-of-concept data for LB2501, the world’s first in vivo CD19/CD20 dual-target CAR-T therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma…
-
A New Era Begins: World’s First Bispecific ADC Iza-bren Approved, Redefining Cancer Treatment and Delivering Early Benefits to Chinese Patients
In June 2026, China’s National Medical Products Administration (NMPA) approved iza-bren (brand name: Yizekang®; generic name: Loncastuximab Eglonatamab), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) independently developed by Biokin Pharmaceutical. The approval is for the treatment of patients with relapsed or metastatic nasopharyngeal carcinoma (NPC) following prior therapy.
-
EHA 2026 | Dr. Yajing Zhang: Moving from Empirical Treatment Toward Mechanism-Driven Precision Stratification in Relapsed/Refractory Hematologic Malignancies
The 2026 European Hematology Association (EHA 2026) Congress was held in Stockholm, Sweden, from June 11–14, 2026. Dr. Yajing Zhang and colleagues from Beijing GoBroad Boren Hospital presented three studies at this year’s meeting, focusing on two critical questions in the management of relapsed/refractory hematologic malignancies.
Connecting Medical Expertise through Media